ABSTRACT:
The nasal delivery of poorly water-soluble drugs faces challenges related to limited bioavailability and poor absorption. Emulsomes, lipid-based nanoparticles combining characteristics of emulsions and liposomes, offer a promising solution by enhancing the solubility, stability, and delivery of hydrophobic compounds. This review discusses the structure, preparation, and characterization of emulsomes for nasal drug delivery, focusing on lipid composition, surfactant use, and functionalization potential. Key physicochemical properties like size, charge, and encapsulation efficiency are also explored, as they influence their effectiveness. Additionally, the review covers emulsome interaction with the nasal mucosa, transport mechanisms, and potential to cross the blood-brain barrier or enter systemic circulation. Strategies to optimize emulsome formulations, including surfactants, targeting ligands, and modifications, are highlighted. In conclusion, emulsomes present a promising platform for improving the nasal delivery of poorly soluble drugs, particularly for treating central nervous system and systemic conditions.
Cite this article:
Rupanshi Sahu, Rakhee Kapadia. Structure and Fate of Emulsomes Designed for the Nasal Delivery of Poorly Water - Soluble Drugs. Research Journal Pharmacy and Technology. 2026;19(3):1454-8. doi: 10.52711/0974-360X.2026.00209
Cite(Electronic):
Rupanshi Sahu, Rakhee Kapadia. Structure and Fate of Emulsomes Designed for the Nasal Delivery of Poorly Water - Soluble Drugs. Research Journal Pharmacy and Technology. 2026;19(3):1454-8. doi: 10.52711/0974-360X.2026.00209 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-3-70
REFERENCE:
1. Singh S, Khurana K, Chauhan SB, Singh I. Emulsomes: new lipidic carriers for drug delivery with special mention to brain drug transport. Future Journal of Pharmaceutical Sciences. 2023; 9(1): 78. Available from: https://doi.org/10.1186/s43094-023-00530-z
2. Fahr A, van Hoogevest P, May S, Bergstrand N, Leigh MLS. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. European Journal of Pharmaceutical Sciences. 2005; 26(3–4): 251–65. doi: 10.1016/j.ejps.2005.05.012.
3. Wang H, Zhao P, Ma R, Jia J, Fu Q. Drug–drug co-amorphous systems: An emerging formulation strategy for poorly water-soluble drugs. Drug Discovery Today. doi: 10.1016/j.drudis.2024.103883.
4. Khan KU, Minhas MU, Badshah SF, Suhail M, Ahmad A, Ijaz S. Overview of nanoparticulate strategies for solubility enhancement of poorly soluble drugs. Life Science. 2022; 291: 120301. doi: 10.1016/j.lfs.2022.120301.
5. van Hoogevest P, Liu X, Fahr A. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective. Expert Opinion on Drug Delivery. 2011; 8(11): 1481–500. doi: 10.1517/17425247.2011.614228.
6. Weerasuriya A, Mizisin AP. The blood-nerve barrier: structure and functional significance. Methods in Molecular Biology. 2011; 149–73. doi: 10.1007/978-1-60761-938-3_6.
7. Vyas SP, Subhedar R, Jain S. Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. The Journal of Pharmcy and Pharmacology. 2006;58(3):321–6. doi: 10.1211/jpp.58.3.0005.
8. Ucisik MH, Küpcü S, Debreczeny M, Schuster B, Sleytr UB. a novel nanocarrier system that uses S-layer proteins and lipidic emulsomes as functionalizing agents. Small. 2013; 9(17): 2895–904. doi: 10.1002/smll.201203116.
9. Raza K, Katare OP, Setia A, Bhatia A, Singh B. Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes. Journal of Microencapsulation. 2013; 30(3): 225–36. doi: 10.3109/02652048.2012.717115.
10. Paliwal R, Paliwal SR, Mishra N, Mehta A, Vyas SP. Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. International Journal of Pharmaceutics. 2009; 380(1–2): 181–8. doi: 10.1016/j.ijpharm.2009.06.026.
11. Zhou X, Chen Z. Preparation and performance evaluation of emulsomes as a drug delivery system for silybin. Archives of Pharmacal Research. 2015; 38: 2193–200. doi: 10.1007/s12272-015-0630-7.
12. Dubey S, Vyas SP. Emulsomes for lipophilic anticancer drug delivery: development, optimization and in vitro drug release kinetic study. International of Journal of Applied Pharmaceutics. 2021; 13: 114–21. doi:10.22159/ijap.2021v13i2.40339
13. Gupta S, Vyas SP. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. Journal of Drug Targeting. 2007; 15(3): 206–17. doi: 10.1080/10611860701195395.
14. Priya S, Desai VM, Singhvi G. Surface modification of lipid-based nanocarriers: A potential approach to enhance targeted drug delivery. ACS omega. 2022; 8(1): 74–86. doi: 10.1021/acsomega.2c05976
15. Malviya V. Preparation and Evaluation of Emulsomes as a Drug Delivery System for Bifonazole. Indian Journal of Pharmaceutical Education and Research. 2021; 55(1): 86–94. doi:10.5530/ijper.55.1.12
16. Abo El-Enin HA, Mostafa RE, Ahmed MF, Naguib IA, A. Abdelgawad M, Ghoneim MM, et al. Assessment of nasal-brain-targeting efficiency of new developed mucoadhesive emulsomes encapsulating an anti-migraine drug for effective treatment of one of the major psychiatric disorders symptoms. Pharmaceutics. 2022; 14(2): 410. doi: 10.3390/pharmaceutics14020410.
17. Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 2015; 5: 123–7. doi: 10.1007/s13205-014-0214-0.
18. Zhang H. Thin-film hydration followed by extrusion method for liposome preparation. Methods in Molecular Biology. 2017; 17–22. doi: 10.1007/978-1-4939-6591-5_2.
19. Keller L-A, Merkel O, Popp A. . Drug Delivery and Translational Research. 2021; 1–23. doi: 10.1007/s13346-020-00891-5.
20. Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, et al. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Journal of Controlled Release. 2018; 281: 139–77. doi: 10.1016/j.jconrel.2018.05.011.
21. Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose to brain delivery: current status and future perspective. Drug Delivery. 2014; 21(2): 75–86. doi: 10.3109/10717544.2013.838713.
22. Bahadur S, Pathak K. Challenges in Targeting Nasal Passage and Nose-to-Brain Delivery via Nanoemulsions. Nasal Drug Delivery and Formulation Development Challenges, Solution. 2023; 59–82. doi:10.1007/978-3-031-23112-4_5
23. Patel RG. Nasal anatomy and function. Facial Plastic Surgery. 2017; 33(01): 3–8. doi: 10.1055/s-0036-1597950.
24. Anderson KJ, Henneberg M, Norris RM. Anatomy of the nasal profile. Journal of Anatomy. 2008; 213(2): 210–6. doi: 10.1111/j.1469-7580.2008.00924.x.
25. El-Zaafarany GM, Soliman ME, Mansour S, Cespi M, Palmieri GF, Illum L, et al. A tailored thermosensitive PLGA-PEG-PLGA/emulsomes composite for enhanced oxcarbazepine brain delivery via the nasal route. Pharmaceutics. 2018; 10(4): 217. doi: 10.3390/pharmaceutics10040217.
26. Lansley AB. Mucociliary clearance and drug delivery via the respiratory tract. Advanced Drug Delivery Reviews. 1993; 11(3): 299–327. https://doi.org/10.1016/0169-409X(93)90014-U
27. Marttin E, Schipper NGM, Verhoef JC, Merkus FWHM. Nasal mucociliary clearance as a factor in nasal drug delivery. Advanced Drug Delivery Review. 1998; 29(1–2): 13–38. doi: 10.1016/s0169-409x(97)00059-8.
28. Inoue D, Tanaka A, Kimura S, Kiriyama A, Katsumi H, Yamamoto A, et al. The relationship between in vivo nasal drug clearance and in vitro nasal mucociliary clearance: Application to the prediction of nasal drug absorption. European Journal of Pharmaceutical Science. 2018; 117: 21–6. doi: 10.1016/j.ejps.2018.01.032.
29. Kapadia R, Jain M, Patel D, Devkar R, Sawant K. Nano-emulsomes for Back of the Eye Delivery of Ganciclovir: Formulation Optimization, Characterization and In vitro/In vivo Evaluation. Pharmaceutical Development and Technology. 2023; (just-accepted): 1–39. doi: 10.1080/10837450.2023.2216784.
30. GILL V, NANDA A. Preparation and characterization of etodolac bearing emulsomes. International Journal of Applied Pharmaceutics. 2020; 166–72. DOI:10.22159/ijap.2020v12i5.38842
31. Kapadia R, Parikh K, Jain M, Sawant K. Topical instillation of triamcinolone a cetonide-loaded e mulsomes for posterior ocular delivery: statistical optimization and in vitro-in vivo studies. Drug Delivery and Translation Research. 2021; 11: 984–99. doi: 10.1007/s13346-020-00810-8.
32. Pal A, Gupta S, Jaiswal A, Dube A, Vyas SP. RETRACTED ARTICLE Development and evaluation of tripalmitin emulsomes for the treatment of experimental visceral leishmaniasis. Journal of Liposome Research. 2012; 22(1): 62–71. doi: 10.3109/08982104.2011.592495.
33. Gill V, Kumar MS, Khurana B, Arora D, Mahadevan N. Development of Amphotericin B Loaded Modified Emulsomes for Visceral Leishmaniasis. International Journal of Recent Advances in Medical and Pharma Research. 2011; 1: 14–20. doi: 10.1208/s12249-016-0553-8.
34. Ucisik MH, Küpcü S, Schuster B, Sleytr UB. Characterization of curcuemulsomes: Nanoformulation for enhanced solubility anddelivery of curcumin. Journal of Nanobiotechnology. 2013; 11: 1–13. doi: 10.1186/1477-3155-11-37
35. Gupta S, Dube A, Vyas SP. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. Journal of Drug Target. 2007; 15(6): 437–44. doi: 10.1080/10611860701453836.
36. Wu HY, Maron R, Tukpah A-M, Weiner HL. Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant. Journal of Immunology. 2010; 185(6): 3401–7. doi: 10.4049/jimmunol.1000836.
37. Lowell GH, Kaminski RW, VanCott TC, Slike B, Kersey K, Zawoznik E, et al. Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG. The Journal of Infectious Disease. 1997; 175(2): 292–301. doi: 10.1093/infdis/175.2.292.